Redhill Biopharma Ltd. (RDHL) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in a report issued on Tuesday morning. The brokerage currently has a $36.00 target price on the biotechnology company’s stock.

RDHL has been the topic of a number of other research reports. Zacks Investment Research raised Redhill Biopharma from a sell rating to a hold rating in a research report on Tuesday, August 29th. UBS AG initiated coverage on Redhill Biopharma in a research report on Wednesday, September 13th. They set a reduce rating on the stock. Roth Capital dropped their price target on Redhill Biopharma from $27.00 to $20.00 and set a buy rating on the stock in a research report on Tuesday, November 14th. Finally, Seaport Global Securities initiated coverage on Redhill Biopharma in a research report on Friday, October 6th. They set a buy rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Redhill Biopharma presently has a consensus rating of Buy and a consensus target price of $21.10.

Redhill Biopharma (NASDAQ:RDHL) opened at $5.02 on Tuesday. Redhill Biopharma has a 1 year low of $4.82 and a 1 year high of $12.09.

Several hedge funds and other institutional investors have recently modified their holdings of RDHL. Renaissance Technologies LLC lifted its position in shares of Redhill Biopharma by 144.1% during the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 36,600 shares during the last quarter. Family Management Corp raised its stake in shares of Redhill Biopharma by 46.6% during the 3rd quarter. Family Management Corp now owns 37,750 shares of the biotechnology company’s stock valued at $408,000 after purchasing an additional 12,000 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Redhill Biopharma during the 1st quarter valued at $101,000. D.A. Davidson & CO. raised its stake in shares of Redhill Biopharma by 10.0% during the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 4,000 shares during the period. Finally, Oppenheimer & Co. Inc. raised its stake in shares of Redhill Biopharma by 10.8% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 2,500 shares during the period. 10.63% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Redhill Biopharma Ltd. (RDHL) Stock Rating Reaffirmed by HC Wainwright” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/25/redhill-biopharma-ltd-rdhl-stock-rating-reaffirmed-by-hc-wainwright.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply